Last reviewed · How we verify
early initiation of treatment with Risperdal Consta
At a glance
| Generic name | early initiation of treatment with Risperdal Consta |
|---|---|
| Sponsor | Janssen Pharmaceutica N.V., Belgium |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis (PHASE4)
- Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: